In N9831, among 5.5% centrally assessed HER2-negative BC, a trend towards benefit with trastuzumab was found (hazard ratio (HR) for DFS, 0.51; 95% CI, 0.21–1.23) [34]. Here, ERBB2 is linked to breast cancer.